Related Experiment Video
Updated: Mar 2, 2026
08:17
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
15.5K
Immune checkpoint blockade for hematologic malignancies: a review.
Matthew J Pianko1, Yuzhou Liu2, Srishti Bagchi1
1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Stem Cell Investigation
|May 23, 2017
Summary
Immune checkpoint blockade, including PD-1/PD-L1 and CTLA-4 targeting, shows promise for blood cancers. Novel strategies and combinations may expand immunotherapy benefits for more hematologic malignancy patients.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Immune checkpoint blockade has transformed cancer treatment.
- Significant responses observed in various cancer types, including hematologic malignancies (HMs).
- Pembrolizumab and nivolumab demonstrate notable efficacy in Hodgkin lymphoma (HL).
Purpose of the Study:
- To review the current status of immune checkpoint blockade drug development in HMs.
- To discuss mechanisms of action, resistance, and potential targets within the tumor microenvironment (TME).
- To highlight emerging strategies for expanding immunotherapy benefits in blood cancers.
Main Methods:
- Review of current literature on immune checkpoint inhibitors in hematologic malignancies.
- Analysis of clinical data for PD-1/PD-L1 and CTLA-4 blockade.
- Exploration of novel combination therapies and immunologic targets.
Main Results:
- PD-1/PD-L1 and CTLA-4 blockade are clinically advanced immune checkpoint strategies.
- These therapies have shown dramatic single-agent responses in Hodgkin lymphoma.
- Emerging strategies focus on innovative combinations to enhance efficacy.
Conclusions:
- Immune checkpoint blockade is a promising therapeutic avenue for hematologic malignancies.
- Understanding resistance mechanisms and TME targets is crucial for optimizing treatment.
- Novel combination approaches hold potential to broaden immunotherapy application in blood cancers.
